3 Month Efficacy Evaluation (Compared to Baseline) Using Validated Symptom Assessment Tools (See Outcome Metrics for Details) Clinical Trial
Official title:
A Prospective Randomized Technology Assessment Trial of Prostate Vaporization Techniques in a Canadian Hospital
Verified date | April 2018 |
Source | Queen's University |
Contact | n/a |
Is FDA regulated | No |
Health authority | |
Study type | Interventional |
Kingston General Hospital is committed to upgrading the surgical treatment platform for
benign prostate surgery. Vaporization Surgery, either laser-vaporization or
electo-vaporization is becoming a "standard" of therapy for benign prostatic hyperplasia
rather than the traditional transurethral resection of the prostate. However many Canadian
hospitals have been slow to adopt an updated program because of evolving competing technology
systems as well as unknown cost, efficacy, complication and patient/surgeon satisfaction
considerations. KGH has been recognized as a centre of excellence in evaluating medical
therapy for BPH and studies from the institution have impacted BPH care nationally and
abroad. Laser and other state of the art BPH surgical technologies are being purchased by
Ontario hospitals, including the local area, with no prospective assessment process. Kingston
is uniquely advantaged to undertake a randomized comparative study of two of the most
promising technology platforms because the investigators have the experience and expertise to
perform the study in a hospital and surgeon naive institution.
The investigators propose to directly compare two vaporization techniques, laser and plasma
vaporization systems. The investigators will be able to answer the most important questions
in technology introduction and technique into our hospital system - cost, efficacy, safety
and satisfaction. The results will inform KGH (and other similar Ontario centres) on the
advantage or not (financial and patient care related) of investing in a BPH state of the art
vaporization technology.
Status | Completed |
Enrollment | 55 |
Est. completion date | July 8, 2016 |
Est. primary completion date | July 8, 2016 |
Accepts healthy volunteers | No |
Gender | Male |
Age group | 45 Years and older |
Eligibility |
Inclusion Criteria: - Male at least 45 years of age. - Peak urinary flow rate at least 4 ml/sec with a voided volume of at least 125 ml. - IPPS symptom score = 12 at screening visit. - Prostate volume on DRE estimated to be > 30cc. - Voluntarily signed informed consent agreement prior to the performance of any study procedures. Exclusion Criteria: - Any prior invasive intervention for BPH. - PSA level greater than 10 ng/ml at screening without either a negative biopsy or documented explanation of why no biopsy was performed. - Medical condition unfit for surgery - History or current evidence of carcinoma of the prostate. - Documented bacterial prostatitis within the past 3 months. - Known severe bleeding disorder. - Unable to follow protocol directions or sign informed consent due to organic brain or psychiatric disease. - History of alcoholism or any other substance abuse, which, in the opinion of the investigator, would affect compliance with the protocol. |
Country | Name | City | State |
---|---|---|---|
Canada | Centre for Applied Urological Research | Kingston | Ontario |
Lead Sponsor | Collaborator |
---|---|
Queen's University |
Canada,
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Primary | Clarion laser vaporization of the prostate | Clarion laser vaporization of the prostate | 3 months | |
Primary | Olympus plasma vaporization of the prostate | Olympus plasma vaporization of the prostate | 3 months |